Bioblast Pharma Ltd (BioBlast) is an Israel-based development-stage biopharmaceutical company. The Company is focused on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic and metabolic diseases. It focuses on therapeutic platforms that offer solutions for several diseases that share a common pathophysiological mechanism, which are the functional changes that accompany a particular syndrome or disease. It also focuses on diseases with severe and debilitating manifestations. The Company has several drug candidates in clinical or preclinical development targeting neuromuscular/central nervous system (CNS) and mitochondrial diseases. Its drug candidates include Trehalose IV Solution, BB-FA (Bioblast-Friedreich's ataxia) and BBrm-02. The Company's product candidate platforms include Protein Stabilizing Platform, Read-through Platform and Mitochondrial Protein Replacement Platform.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Symbol: NASDAQ:ORPN
- CUSIP: N/A
- Web: www.bioblast-pharma.com
- Market Cap: $7.38 million
- Outstanding Shares: 16,391,000
- 50 Day Moving Avg: $0.53
- 200 Day Moving Avg: $1.00
- 52 Week Range: $0.41 - $2.24
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -0.62
- P/E Growth: 0.00
- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $0.53 per share
- Price / Book: 0.85
- EBIDTA: ($13,930,000.00)
- Return on Equity: -52.90%
- Return on Assets: -46.88%
- Current Ratio: 6.67%
- Quick Ratio: 6.67%
- Average Volume: 82,100 shs.
- Beta: 0.16
- Short Ratio: 1.74
Frequently Asked Questions for Bioblast Pharma Ltd (NASDAQ:ORPN)
What is Bioblast Pharma Ltd's stock symbol?
Bioblast Pharma Ltd trades on the NASDAQ under the ticker symbol "ORPN."
How were Bioblast Pharma Ltd's earnings last quarter?
Bioblast Pharma Ltd (NASDAQ:ORPN) announced its earnings results on Thursday, August, 25th. The company reported ($0.22) earnings per share for the quarter, beating analysts' consensus estimates of ($0.27) by $0.05. During the same quarter in the previous year, the business earned ($0.26) EPS. View Bioblast Pharma Ltd's Earnings History.
Where is Bioblast Pharma Ltd's stock going? Where will Bioblast Pharma Ltd's stock price be in 2017?
2 equities research analysts have issued 1-year price targets for Bioblast Pharma Ltd's stock. Their forecasts range from $0.63 to $15.00. On average, they anticipate Bioblast Pharma Ltd's share price to reach $7.82 in the next year. View Analyst Ratings for Bioblast Pharma Ltd.
Who are some of Bioblast Pharma Ltd's key competitors?
Some companies that are related to Bioblast Pharma Ltd include Repros Therapeutics (RPRX), Onconova Therapeutics (ONTX), Celsion (CLSN), Mateon Therapeutics (MATN), RXi Pharmaceuticals Corp (RXII), Cerulean Pharma (CERU), OncoGenex Pharmaceuticals (OGXI), Jaguar Animal Health (JAGX), Windtree Therapeutics (WINT), Ritter Pharmaceuticals (RTTR), Ampliphi Biosciences Corp (APHB), Opexa Therapeutics (OPXA), Affymax (AFFY), Tetralogic Pharmaceuticals Corp (TLOG), Aegerion Pharmaceuticals (AEGR), Anacor Pharmaceuticals (ANAC), Ariad Pharmaceuticals (ARIA) and Baxalta (BXLT).
Who owns Bioblast Pharma Ltd stock?
Who sold Bioblast Pharma Ltd stock? Who is selling Bioblast Pharma Ltd stock?
Who bought Bioblast Pharma Ltd stock? Who is buying Bioblast Pharma Ltd stock?
How do I buy Bioblast Pharma Ltd stock?
Shares of Bioblast Pharma Ltd can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Bioblast Pharma Ltd stock cost?
One share of Bioblast Pharma Ltd stock can currently be purchased for approximately $0.45.
Earnings History for Bioblast Pharma Ltd (NASDAQ:ORPN)Earnings History by Quarter for Bioblast Pharma Ltd (NASDAQ:ORPN)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Bioblast Pharma Ltd (NASDAQ:ORPN)
Current Year EPS Consensus Estimate: $-0.8200 EPS
Next Year EPS Consensus Estimate: $-0.7300 EPS
Dividend History for Bioblast Pharma Ltd (NASDAQ:ORPN)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Bioblast Pharma Ltd (NASDAQ:ORPN)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Bioblast Pharma Ltd (NASDAQ:ORPN)
Latest Headlines for Bioblast Pharma Ltd (NASDAQ:ORPN)
Bioblast Pharma Ltd (ORPN) Chart for Friday, May, 26, 2017